Regeneron Q2 Revenue Hits $4.3 Billion, Up 17% YoY — EPS Beats Estimates

Regeneron announced in an SEC Form 8-K filing that its second-quarter 2026 revenue reached $4.3 billion, up 17% year-over-year.

Quarter at a Glance

Regeneron's second-quarter revenue of $4.3 billion topped market estimates. Dupixent, Eylea HD, and Libtayo all posted record sales, driving the results.

• Revenue: $4.3 billion, up 17% year-over-year
• GAAP EPS: $12.23, down 5% from $12.81 a year earlier
• Non-GAAP EPS: $14.29, beating estimates by $3.71, up 11% year-over-year
• GAAP net income: $1.3 billion, down 7% year-over-year
• Non-GAAP net income: $1.5 billion, up 8% year-over-year

Outlook for Next Quarter

Regeneron CFO Christopher Fenimore said the company fully repaid its Sanofi development balance by the end of the second quarter. The balance reflected amounts owed to Sanofi for shared research and development costs. Fenimore said the repayment would meaningfully improve collaboration profitability starting in the third quarter. The company deployed nearly $3.0 billion in the first half of the year on share buybacks, dividends, capital expenditures, and business development.

Market Reaction

Foreign media outlets noted that the results beat market estimates on both revenue and earnings per share. Financial outlet ChartMill reported that shares rose following the earnings release. Investing.com reported that non-GAAP EPS exceeded estimates by $3.71. Ahead of the release, the key question was whether Dupixent's growth could offset a slowdown in Eylea sales.

By Business Segment

• Dupixent (as recorded by Sanofi) global sales: $6.0 billion, a record, up 38% year-over-year
• Eylea HD U.S. sales: $596 million, a record, up 52% year-over-year
• Eylea U.S. sales: $412 million, down 45% year-over-year
• Libtayo global sales: $489 million, a record, up 30% year-over-year
• Sanofi collaboration revenue: $2.17 billion, up 51% year-over-year

This article was automatically generated based on the original SEC Form 8-K filing and foreign media reports, with the goal of quickly delivering key data right after the announcement. Readers are advised to review the company's official filing before making trading decisions. Prices reflect the time of writing and may differ from current levels.